Pertuzumab
- Generic Name
- Pertuzumab
- Brand Names
- Perjeta, Perjeta-Herceptin, Phesgo
- Drug Type
- Biotech
- CAS Number
- 380610-27-5
- Unique Ingredient Identifier
- K16AIQ8CTM
- Background
Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. It was first approved by the FDA in 2012 for use with docetaxel and another HER2-targeted monoclonal antibody, trastuzumab, in the treatment of metastatic HER2-positive breast cancer. Its indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence.
- Indication
Pertuzumab is indicated for intravenous administration in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated in combination with trastuzumab and other chemotherapies for the neoadjuvant treatment of HER2-positive locally advanced, inflammatory, or early-stage breast cancer as part of a complete treatment regimen and as adjuvant treatment in patients with HER2-positive early-stage breast cancer at high risk of recurrence.
Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - in the treatment of HER2-positive breast cancers in adults.
- Associated Conditions
- Inflammatory Breast Cancer (IBC), Locally Advanced Breast Cancer (LABC), Metastatic Breast Cancer, Stage I Breast Cancer
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
- Conditions
- Locally Advanced Malignant NeoplasmBreast Cancer
- Interventions
- Other: DOT imagingProcedure: SurgeryDrug: PremedicationDrug: Anti-nausea therapy
- First Posted Date
- 2013-05-06
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 10
- Registration Number
- NCT01847001
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 208
- Registration Number
- NCT01835236
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Aarau, Switzerland
🇨🇭Kantonspital Aarau, Aarau, Switzerland
🇨🇭Kantonsspital Baden, Baden, Switzerland
A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-03-25
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- West German Study Group
- Target Recruit Count
- 220
- Registration Number
- NCT01817452
- Locations
- 🇩🇪
Ev. Krankenhaus Bethesda Brustzentrum Niederrhien, Moenchengladbach, Germany
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
- Conditions
- Breast Cancer
- Interventions
- Procedure: MastectomyRadiation: Radiation Therapy
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 23
- Registration Number
- NCT01796197
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2013-01-24
- Last Posted Date
- 2020-12-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 780
- Registration Number
- NCT01774786
- Locations
- 🇺🇸
Florida Cancer Specialists - SCRI; Pharmacy, Fort Myers, Florida, United States
🇺🇸Weill Medical College of Cornell University; Division of Hematology & Medical Oncology, New York, New York, United States
🇺🇸University Of Chicago Medical Center; Section Of Hematology/Oncology, Chicago, Illinois, United States
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
- Conditions
- HER2-positive Breast CancerRecurrent Breast CancerStage IIA Breast CancerStage IIB Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerBreast AdenocarcinomaInflammatory Breast Carcinoma
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2012-11-21
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT01730833
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸City of Hope Antelope Valley, Lancaster, California, United States
🇺🇸City of Hope- South Pasadena Cancer Center, South Pasadena, California, United States
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2012-09-13
- Last Posted Date
- 2017-05-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 208
- Registration Number
- NCT01684878
- Locations
- 🇳🇱
Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands
🇳🇱Academisch Ziekenhuis Leiden; Clinical Oncology, Leiden, Netherlands
🇳🇱UMC St Radboud, Nijmegen, Netherlands
A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer
- First Posted Date
- 2012-08-28
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 95
- Registration Number
- NCT01674062
Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1
- Conditions
- Elderly Metastatic Breast Cancer Population
- Interventions
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2022-11-17
- Target Recruit Count
- 80
- Registration Number
- NCT01597414
- Locations
- 🇵🇹
Champalimaud Cancer Center, Lisboa, Portugal
🇫🇷Centre Paul Strauss, Strasbourg, France
🇳🇱VieCuri - Medisch Centrum voor Noord-Limburg - Locatie Venlo, Venlo, Netherlands
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1436
- Registration Number
- NCT01572038
- Locations
- 🇦🇷
Centro Oncologico Riojano Integral (CORI), La Rioja, Argentina
🇦🇹LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz, Austria
🇧🇪UZ Brussel, Brussel, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.